Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Mar 14, 2014 (13 years ago)

VPRIV¿ (velaglucerase alfa for injection)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

VPRIV¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.

Affected NDC 54092-0701-04

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Vpriv
velaglucerase alfa
NDC 54092-0701
2.5 mg/mL Injection, Powder, Lyophilized, for Solution
Intravenous
Takeda Pharmaceuticals America, Inc. Rx
Recalling firm
Shire Human Genetic Therapies, Inc.
Origin
MA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1251-2014 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Shire Human Genetic Therapies, Inc.

All 2014 recalls
Class I · High risk

Natpara (parathyroid hormone)

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Terminated Packaging defect Shire Human Genetic Therapies, Inc. D-0038-2020
Class I · High risk

Natpara (parathyroid hormone)

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Terminated Packaging defect Shire Human Genetic Therapies, Inc. NDC 68875-0204-02 D-0037-2020
Class I · High risk

Natpara (parathyroid hormone)

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Terminated Packaging defect Shire Human Genetic Therapies, Inc. NDC 68875-0203-02 D-0036-2020
Class I · High risk

Natpara (parathyroid hormone)

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Terminated Packaging defect Shire Human Genetic Therapies, Inc. NDC 68875-0202-02 D-0035-2020

Other particulate / foreign matter recalls from 2014

All particulate / foreign matter recalls
Class II · Moderate risk

Propofol Injectable Emulsion

Presence of Particulate Matter: The firm received a complaint of an embedded particulate in the neck of one vial composed primarily of iron.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4699-30 D-0381-2015
Class I · High risk

0.9% Sodium Chloride Injection USP

Presence of Particulate Matter: Confirmed customer complaints received for the presence of blue plastic, identified as fragments of the frangible from the vial adapter.

Terminated Particulate / foreign matter Baxter Healthcare Corp NDC 0338-0553-18 D-481-2015